Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Tratamiento complementario con rufinamida para la epilepsia refractaria

Esta versión no es la más reciente

ver la versión actual 08 noviembre 2020

Información

DOI:
https://doi.org/10.1002/14651858.CD011772.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 25 abril 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Epilepsia

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Mariangela Panebianco

    Correspondencia a: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

    [email protected]

    [email protected]

  • Hemanshu Prabhakar

    Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India

  • Anthony G Marson

    Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Contributions of authors

MP was primarily responsible for the writing of this review and completing data extraction and 'Risk of bias' assessments.

AGM provided guidance and manuscript feedback.

HP assessed the studies for eligibility, extracted data and assessed risk of bias.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • National Institute for Health Research, UK.

    This review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National health Service (NHS) or the Department of Health.

Declarations of interest

MP: none known.

AGM: a consortium of pharmaceutical companies (GSK, Eisai, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).

HP: none known.

Acknowledgements

This review update was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2020 Nov 08

Rufinamide add‐on therapy for drug‐resistant epilepsy

Review

Mariangela Panebianco, Hemanshu Prabhakar, Anthony G Marson

https://doi.org/10.1002/14651858.CD011772.pub3

2018 Apr 25

Rufinamide add‐on therapy for refractory epilepsy

Review

Mariangela Panebianco, Hemanshu Prabhakar, Anthony G Marson

https://doi.org/10.1002/14651858.CD011772.pub2

2015 Jun 25

Rufinamide add‐on therapy for refractory epilepsy

Protocol

Mariangela Panebianco, Anthony G Marson

https://doi.org/10.1002/14651858.CD011772

Differences between protocol and review

None.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.